Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session
06 mars 2017 08h30 HE
|
Esperion Therapeutics, Inc.
Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time ANN ARBOR, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management...
Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
25 janv. 2017 08h05 HE
|
Esperion Therapeutics, Inc.
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD...
Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
09 janv. 2017 08h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
08 janv. 2017 16h00 HE
|
Esperion Therapeutics, Inc.
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...
Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
04 janv. 2017 17h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
SECURITIES NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important March 14, 2016 Deadline in Class Action – ESPR
04 mars 2016 15h30 HE
|
The Rosen Law Firm PA
NEW YORK, March 04, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. -- ESPR
11 févr. 2016 16h40 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Esperion Therapeutics, Inc....